Estamos no ar no ! Saiba mais

Evolus

EOLS

Valor de mercado US$ 469 mi

7,10 USD

-0,47

6,21%

No fechamento Atualizado 16 de out. 16:00 EDT

1 dia

-6,21%

5 dias

-8,51%

1 mês

-11,14%

3 meses

26,11%

6 meses

56,73%

No acumulado do ano

5,65%

1 ano

12,7%

5 anos

-8,51%

10 anos

-38,26%

Sobre: Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.

Funcionários: 353

Saúde Fabricantes de medicamentos — especializados e genéricos

Notícias

Positivo

Neutro

Negativo

Sentimento 3 meses

Positivo 25%

Neutro 68,8%

Negativo 6,3%

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS

NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Evolus, Inc. ("Evolus" or the "Company") (NASDAQ: EOLS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS

Evolus Expands Innovation Pipeline with Novel Injectable Hair Restoration Program

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it has entered into an option agreement with a privately held company developing a novel, procedure-based, sustained-release injectable treatment for hair restoration.The agreement advances Evolus' business development strategy by adding a potential new category that is complementary to its existing injec.

Evolus Expands Innovation Pipeline with Novel Injectable Hair Restoration Program

EOLS Investors with $100,000 in Losses Have Opportunity to Join Evolus, Inc. Fraud Investigation with SBS Law

LOS ANGELES--(BUSINESS WIRE)---- $EOLS--EOLS Investors with $100,000 in Losses Have Opportunity to Join Evolus, Inc. Fraud Investigation with SBS Law.

EOLS Investors with $100,000 in Losses Have Opportunity to Join Evolus, Inc. Fraud Investigation with SBS Law

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS

NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Evolus, Inc. ("Evolus" or the "Company") (NASDAQ: EOLS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS

NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Evolus, Inc. (“Evolus” or the “Company”) (NASDAQ: EOLS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS

Evolus Warned Over Misbranding in Social Media Promo for Frown Lines Drug

The U.S. Food and Drug Administration's Office of Prescription Drug Promotion in September issued a warning letter to Evolus Inc. (NASDAQ:EOLS) regarding misleading Instagram promotional posts for its injectable prescription drug, Jeuveau (prabotulinumtoxinA-xvfs).

Evolus Warned Over Misbranding in Social Media Promo for Frown Lines Drug

Evolus Launches Wings by Evolus, a New Charitable Platform to Mobilize Its Community in Support of Important Causes

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the launch of Wings by Evolus, a new charitable platform designed to bring together aesthetic practices, providers, and patients to support organizations and causes that positively impact their communities. The first Wings by Evolus initiative will launch in October in recognition of Breast Cancer Awareness M.

Evolus Launches Wings by Evolus, a New Charitable Platform to Mobilize Its Community in Support of Important Causes

Zacks Investment Research

Wall Street Analysts Think Evolus (EOLS) Could Surge 77.68%: Read This Before Placing a Bet

The mean of analysts' price targets for Evolus (EOLS) points to a 77.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think Evolus (EOLS) Could Surge 77.68%: Read This Before Placing a Bet

Zacks Investment Research

Wall Street Analysts Believe Evolus (EOLS) Could Rally 106.08%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 106.1% in Evolus (EOLS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe Evolus (EOLS) Could Rally 106.08%: Here's is How to Trade

Evolus: The Injectable Platform Is Becoming The Real Moat

Evolus is evolving into a multi-product aesthetics platform, leveraging its distribution network and loyalty ecosystem to drive operating leverage and recurring revenue. Q2 2026 results showed 21% revenue growth, positive adjusted EBITDA, and raised guidance, with management projecting 2028 revenue of $450M–$500M and EBITDA margins of 13–15%. Evolus trades at a forward EV/Sales of 1.86, a 50% discount to sector median, but requires margin expansion to justify valuation as it transitions from single-product to platform economics.

Evolus: The Injectable Platform Is Becoming The Real Moat

Ver ranking de notícias

Gráficos de preços implementados com Lightweight Charts™